ASCC1

ASCC1 is a multidomain regulatory subunit of the ASCC (activating signal cointegrator) complex that coordinates the cellular response to DNA alkylation damage (PMID:29997253). It physically interacts with the ASCC3 helicase, and its loss produces excess ASCC3 foci that fail to recruit ASCC2 during alkylation damage, establishing ASCC1 as an organizer of proper ASCC complex assembly and recruitment (PMID:29997253). ASCC1 knockout sensitizes cells to alkylating agents in a manner genetically epistatic with ASCC3, placing the two proteins in a common alkylation-repair pathway (PMID:29997253). Under basal conditions ASCC1 resides in nuclear speckles and relocalizes from them upon alkylation damage, a dynamic behavior dependent on a C-terminal RNA-binding motif (PMID:29997253). Structurally, ASCC1 combines a KH domain bearing a Helix-Clasp-Helix motif that confers sequence-specific binding to CGCG-containing RNA with a two-histidine phosphodiesterase (PDE) domain whose active-site architecture is configured for cyclic phosphate hydrolysis, and these two RNA-binding surfaces are aligned in solution for a coordinated RNA-binding function (PMID:38750793). Beyond its DNA-damage role, ASCC1 inhibits NF-κB transcriptional activation and suppresses inflammatory target-gene expression and TNF-α secretion (PMID:26503956), and it promotes osteoblast differentiation while restraining adipogenesis in mesenchymal stromal cells through RUNX2 and TGF-β/SMAD signaling (PMID:37455927). Loss-of-function and splicing variants in ASCC1 have been linked to disease, with patient-derived evidence that PDE-domain missense variants abolish ASCC1 protein in muscle (PMID:41230573).

1. 2015 Medium

   Established the first functional role for ASCC1 outside complex assembly by showing it acts as a negative regulator of inflammatory transcription, and that a truncating variant abolishes this activity.

   Evidence NF-κB-luciferase reporter, qRT-PCR of target genes, and TNF-α ELISA comparing full-length versus p.S78* ASCC1 across five human cell lines

   PMID:26503956

   Open questions at the time

   • Direct molecular target/interaction by which ASCC1 inhibits NF-κB not identified
   • Relationship between this transcriptional role and the ASCC complex/alkylation function unresolved
2. 2018 High

   Defined ASCC1 as a physical and genetic partner of ASCC3 that organizes proper ASCC complex assembly and recruitment during alkylation damage, answering where ASCC1 acts in the repair pathway.

   Evidence Co-IP, CRISPR/Cas9 knockout with ASCC2/ASCC3 foci imaging, alkylation sensitivity, and epistasis with ASCC3 in human cells

   PMID:29997253

   Open questions at the time

   • Molecular basis of how ASCC1 promotes ASCC2 recruitment to foci not resolved
   • Whether ASCC1 enzymatic activity contributes to repair untested
3. 2018 Medium

   Showed ASCC1 localization is dynamic and RNA-motif-dependent, linking its subcellular behavior to damage signaling.

   Evidence Fluorescence microscopy of nuclear speckle localization plus mutational analysis of the C-terminal RNA-binding motif

   PMID:29997253

   Open questions at the time

   • Identity of the RNA recognized in speckles not determined
   • Functional purpose of speckle exit upon damage unclear
4. 2023 Medium

   Extended ASCC1 function to stromal cell fate, showing it drives osteoblastogenesis at the expense of adipogenesis via defined transcriptional and signaling effectors.

   Evidence siRNA knockdown in hMSCs with differentiation, mineralization, and lipid assays plus proteomics/RNA-seq implicating RUNX2, SERPINF1, and TGF-β/SMAD

   PMID:37455927

   Open questions at the time

   • Whether ASCC1 acts directly or indirectly on RUNX2/TGF-β not established
   • Connection to the ASCC complex or RNA-binding activity not addressed
5. 2024 High

   Provided structural mechanism for ASCC1 RNA recognition and putative catalysis, defining a CGCG-specific KH/HCH motif and a PDE active site poised for cyclic phosphate hydrolysis.

   Evidence X-ray crystallography of Alvinella pompejana and human ASCC1 domains, SAXS, RNA-binding assays, and evolutionary analysis

   PMID:38750793

   Open questions at the time

   • Physiological RNA substrate of the PDE activity not identified
   • Catalytic activity not demonstrated biochemically on a defined substrate
   • Link between RNA binding/catalysis and alkylation repair untested
6. 2025 Low

   Connected ASCC1 disease variants to protein-level loss of function, showing a conserved PDE-domain missense variant nearly eliminates ASCC1 protein.

   Evidence Patient muscle protein expression analysis with exome/Sanger sequencing (single case)

   PMID:41230573

   Open questions at the time

   • Single case without in vitro functional confirmation
   • Mechanism linking ASCC1 loss to muscle/neuromuscular phenotype not established
   • Domain-specific contribution of PDE versus KH to disease unresolved

• The physiological RNA substrate of the ASCC1 PDE domain and the mechanistic link between its RNA-binding/catalytic activities and its roles in alkylation repair, NF-κB regulation, and stromal differentiation remain unknown.
• No demonstrated catalytic turnover on an endogenous substrate
• No unifying model connecting structural function to the multiple cellular phenotypes